<DOC>
	<DOCNO>NCT02179671</DOCNO>
	<brief_summary>Primary objective : To assess efficacy various sequence either small molecule IMT ( IMT-A ) follow IMT-B ( MEDI4736 ) .</brief_summary>
	<brief_title>Immune-Modulated Study Selected Small Molecules ( Gefitinib , AZD9291 , Selumetinib + Docetaxel ) 1st Immune-Mediated Therapy ( IMT ; Tremelimumab ) With Sequential Switch 2nd IMT ( MEDI4736 ) Patients With Locally Advanced Metastatic Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description>This multi-arm , multi-cohort , Phase IIa , open-label study select small molecule ( gefitinib , AZD9291 , selumetinib + docetaxel ) 1st IMT ( hereafter refer IMT-A ; tremelimumab ) follow sequential switch 2nd IMT ( hereafter refer IMT-B ; MEDI4736 ) locally advanced metastatic NSCLC ( Stage IIIB-IV ) . Patients enrol concurrently multiple cohort .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Osimertinib</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Provision archive tumor tissue sample mandatory tissue biopsy Patients must either histologically cytologically document NSCLC present locally advanced metastatic stage IIIBIV disease Life expectancy â‰¥12 week Patients must measurable disease least 1 lesion previously irradiate World Health Organization ( WHO ) performance status 0 1 Mixed small cell NSCLC histology Prior exposure antiPD1 antiPDL1 antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Lung cancer ; NSCLC</keyword>
</DOC>